5 Best Longevity Stocks to Buy Now

3. Gilead Sciences, Inc. (NASDAQ:GILD)

On June 5, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) applauded the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. CEO Daniel O’Day said South Africa is “at the heart of global efforts to end HIV,” and that Gilead is working with country leadership, the Global Fund, and the U.S. State Department through PEPFAR to bring lenacapavir to communities most in need ahead of a broader rollout of generic versions.

On June 2, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced Phase 3 results in primary biliary cholangitis showing that Livdelzi led to significantly more patients achieving normalization of alkaline phosphatase, or ALP, compared with placebo after 52 weeks. The primary endpoint was defined as ALP less than or equal to 1.0 upper limit of normal and a greater than or equal to 15% decrease from baseline. Cynthia Levy of the University of Miami Miller School of Medicine said the IDEAL results further support the efficacy and safety profile of Livdelzi.

On May 27, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) shared post hoc analysis data from the ongoing Phase 3 ASSURE study showing high and sustained ALP normalization rates in people with primary biliary cholangitis. Among 50 participants, 83% of evaluable participants achieved composite ALP normalization at 12 months, while 74% achieved the same endpoint at 24 months. Gilead said Livdelzi was generally well tolerated, with no treatment discontinuations due to adverse events and no new safety signals observed with up to two years of follow-up.

Gilead Sciences, Inc. (NASDAQ:GILD) discovers, develops, and commercializes medicines in areas of unmet medical need in the United States, Europe, and internationally.